RhumbLine Advisers’s Seres Therapeutics MCRB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-2,756
| Closed | -$39.9K | – | 4278 |
|
|
2024
Q2 | $39.9K | Sell |
2,756
-4,317
| -61% | -$72K | ﹤0.01% | 3740 |
|
|
2024
Q1 | $109K | Buy |
7,073
+197
| +3% | +$4.25K | ﹤0.01% | 3418 |
|
|
2023
Q4 | $193K | Buy |
6,876
+48
| +0.7% | +$1.26K | ﹤0.01% | 3206 |
|
|
2023
Q3 | $325K | Buy |
6,828
+88
| +1% | +$6.72K | ﹤0.01% | 2885 |
|
|
2023
Q2 | $646K | Buy |
6,740
+2,025
| +43% | +$220K | ﹤0.01% | 2532 |
|
|
2023
Q1 | $535K | Buy |
4,715
+234
| +5% | +$25.3K | ﹤0.01% | 2402 |
|
|
2022
Q4 | $502K | Buy |
4,481
+85
| +2% | +$11.4K | ﹤0.01% | 2456 |
|
|
2022
Q3 | $564K | Buy |
4,396
+473
| +12% | +$48.4K | ﹤0.01% | 2439 |
|
|
2022
Q2 | $269K | Sell |
3,923
-206
| -5% | -$17.7K | ﹤0.01% | 2811 |
|
|
2022
Q1 | $588K | Sell |
4,129
-8
| -0.2% | -$1.23K | ﹤0.01% | 2347 |
|
|
2021
Q4 | $689K | Buy |
4,137
+59
| +1% | +$9.38K | ﹤0.01% | 2369 |
|
|
2021
Q3 | $568K | Buy |
4,078
+136
| +3% | +$26.6K | ﹤0.01% | 2486 |
|
|
2021
Q2 | $1.88M | Buy |
3,942
+412
| +12% | +$174K | ﹤0.01% | 1977 |
|
|
2021
Q1 | $1.45M | Sell |
3,530
-251
| -7% | -$116K | ﹤0.01% | 2037 |
|
|
2020
Q4 | $1.85M | Buy |
3,781
+472
| +14% | +$276K | ﹤0.01% | 1884 |
|
|
2020
Q3 | $1.87M | Buy |
3,309
+504
| +18% | +$168K | ﹤0.01% | 1719 |
|
|
2020
Q2 | $267K | Buy |
2,805
+508
| +22% | +$44.6K | ﹤0.01% | 2633 |
|
|
2020
Q1 | $164K | Hold |
2,297
| – | – | ﹤0.01% | 2646 |
|
|
2019
Q4 | $158K | Buy |
2,297
+180
| +9% | +$13.3K | ﹤0.01% | 2803 |
|
|
2019
Q3 | $170K | Buy |
2,117
+275
| +15% | +$18.2K | ﹤0.01% | 2785 |
|
|
2019
Q2 | $119K | Buy |
1,842
+497
| +37% | +$47.2K | ﹤0.01% | 2900 |
|
|
2019
Q1 | $185K | Sell |
1,345
-12
| -0.9% | -$1.46K | ﹤0.01% | 2763 |
|
|
2018
Q4 | $123K | Buy |
1,357
+445
| +49% | +$62.3K | ﹤0.01% | 2850 |
|
|
2018
Q3 | $138K | Sell |
912
-66
| -7% | -$10.7K | ﹤0.01% | 2817 |
|
|
2018
Q2 | $168K | Buy |
978
+42
| +4% | +$6.86K | ﹤0.01% | 2777 |
|
|
2018
Q1 | $137K | Sell |
936
-18
| -2% | -$3.45K | ﹤0.01% | 2686 |
|
|
2017
Q4 | $194K | Sell |
954
-184
| -16% | -$37.8K | ﹤0.01% | 2641 |
|
|
2017
Q3 | $365K | Buy |
1,138
+14
| +1% | +$3.83K | ﹤0.01% | 2474 |
|
|
2017
Q2 | $254K | Buy |
1,124
+145
| +15% | +$29.8K | ﹤0.01% | 2638 |
|
|
2017
Q1 | $221K | Buy |
979
+28
| +3% | +$5.68K | ﹤0.01% | 2620 |
|
|
2016
Q4 | $188K | Buy |
951
+164
| +21% | +$35.8K | ﹤0.01% | 2690 |
|
|
2016
Q3 | $193K | Buy |
787
+15
| +2% | +$5.26K | ﹤0.01% | 2692 |
|
|
2016
Q2 | $448K | Buy |
772
+359
| +87% | +$211K | ﹤0.01% | 2258 |
|
|
2016
Q1 | $220K | Buy |
413
+27
| +7% | +$14.1K | ﹤0.01% | 2693 |
|
|
2015
Q4 | $271K | Buy |
+386
| New | +$254K | ﹤0.01% | 2635 |
|
Other funds holding MCRB
FP
SSA
RhumbLine Advisers's MCRB Position: Q3 2024 in Review
RhumbLine Advisers sold out of Seres Therapeutics (MCRB) in Q3 2024, closing a stake of 2,756 shares — an estimated $39.9K sold.
RhumbLine Advisers first reported a position in MCRB in Q4 2015 and held it in 35 quarters. The position peaked at $1.88M in Q2 2021. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2024.
- RhumbLine Advisers reported no remaining Seres Therapeutics position as of Q3 2024 after selling out during the quarter.
- RhumbLine Advisers sold 2,756 Seres Therapeutics shares in Q3 2024, an estimated $39.9K.
- RhumbLine Advisers first reported a position in Seres Therapeutics in Q4 2015 and held it in 35 quarters.
- RhumbLine Advisers's Seres Therapeutics position peaked at $1.88M in Q2 2021.
- 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2024.
Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.